Neurophet to Pursue Global Partnerships and Business Deals and Agreements at BIO USA
1 June 2024
Neurophet, an AI solution company specializing in brain disease, has announced its participation in the BIO International Convention 2024 (BIO USA), scheduled from June 3 to 6 in San Diego, U.S.
At BIO USA, Neurophet will present its Imaging CRO (Contract Research Organization) service, which supports clinical trials for Alzheimer's disease treatment. This service utilizes Neurophet's brain MRI analysis software, "Neurophet AQUA," and brain PET image analysis software, "Neurophet SCALE PET," both approved by the U.S. Food and Drug Administration (FDA) through 510(k) clearance.
Neurophet’s Imaging CRO service provides high-quality, compliant image data analysis, ensuring consistent and reliable results. It is both cost-effective and time-efficient, aiding pharmaceutical and biotech companies throughout the clinical trial process, from patient group selection to efficacy analysis and side effect monitoring. This service aims to enhance the success rates of new drug development.
In a recent partnership, Neurophet has joined forces with AriBio, a developer of neurodegenerative disorder treatments, to support and conduct joint research in the global phase 3 clinical trial of AR1001, an oral treatment for Alzheimer's disease.
"Pharmaceutical companies are increasingly collaborating with AI firms to overcome traditional drug development challenges".
"Our Imaging CRO service provides a significant opportunity for global pharmaceutical companies developing Alzheimer's treatments, contributing to successful clinical trials and improving operational efficiency."
He added, "Neurophet’s brain image analysis technology has attracted significant interest and engagement at various global exhibitions and business events. We are committed to fostering meaningful partnerships, with numerous meetings scheduled with global pharmaceutical companies at BIO USA."
BIO USA is the world’s largest event in the bio industry, bringing together pharmaceutical and bio companies, university research institutes, and investment firms for global partnering opportunities.
Source: prnewswire.com
